Celltrion Leads Xolair Biosimilar Race With US FDA Application
The Application Was Based On The Totality of Evidence From Several Trials
This marks Celltrion’s second regulatory submission for an omalizumab biosimilar as the US formulation patent protecting originator Xolair is set to expire late next year.
